ImmuCell Stock (NASDAQ: ICCC) stock price, news, charts, stock research, profile.
Open | - |
Close | - |
Volume / Avg. | 0 / 8.042K |
Day Range | - - - |
52 Wk Range | 4.260 - 6.050 |
Market Cap | $37.556M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 48 |
Short Interest | 0.07% |
Days to Cover | 1 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of ImmuCell (NASDAQ: ICCC) through any online brokerage.
Other companies in ImmuCell’s space includes: Estrella Immunopharma (NASDAQ:ESLA), OncoCyte (NASDAQ:OCX), Gain Therapeutics (NASDAQ:GANX), Immuneering (NASDAQ:IMRX) and Bolt Biotherapeutics (NASDAQ:BOLT).
The latest price target for ImmuCell (NASDAQ: ICCC) was reported by Aegis Capital on Monday, July 13, 2020. The analyst firm set a price target for 14.00 expecting ICCC to rise to within 12 months (a possible 191.67% upside). 0 analyst firms have reported ratings in the last year.
The stock price for ImmuCell (NASDAQ: ICCC) is $4.8 last updated April 25, 2024 at 8:41 AM EDT.
There are no upcoming dividends for ImmuCell.
ImmuCell’s Q2 earnings are confirmed for Thursday, August 8, 2024.
There is no upcoming split for ImmuCell.
ImmuCell is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.